Evidence map›Paper›PMID 30767148›Full record

ArticleEndocrine pathology2019

MiRNA-3653 Is a Potential Tissue Biomarker for Increased Metastatic Risk in Pancreatic Neuroendocrine Tumours.

Preetjote Gill, Edward Kim, Terence C Chua, Roderick J Clifton-Bligh, Christopher B Nahm, Anubhav Mittal, Anthony J Gill, Jaswinder S Samra

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Endocrine pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. The Role of MiRNA in Cancer: Pathogenesis, Diagnosis, and Treatment.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Preetjote GillUpper Gastrointestinal Surgical Unit, Royal North Shore Hospital, Sydney, Australia.
Edward KimSydney Medical School, University of Sydney, Sydney, Australia.
Terence C ChuaUpper Gastrointestinal Surgical Unit, Royal North Shore Hospital, Sydney, Australia.
Roderick J Clifton-BlighSydney Medical School, University of Sydney, Sydney, Australia.
Christopher B NahmUpper Gastrointestinal Surgical Unit, Royal North Shore Hospital, Sydney, Australia.
Anubhav MittalUpper Gastrointestinal Surgical Unit, Royal North Shore Hospital, Sydney, Australia.
Anthony J GillSydney Medical School, University of Sydney, Sydney, Australia. affgill@med.usyd.edu.au.
Jaswinder S SamraUpper Gastrointestinal Surgical Unit, Royal North Shore Hospital, Sydney, Australia. jas.samra@bigpond.com.
Royal North Shore Hospital · AUUniversity of Sydney · AU

Funding

Ipsen Biopharmaceuticals N/A
6 · The paper itself

Abstract

Pancreatic neuroendocrine tumours (PNETs) are relatively uncommon, accounting for 1-2% of all pancreatic neoplasms. Tumour grade (based on the Ki67 proliferative index and mitotic rate) is associated with metastatic risk across large cohorts; however, predicting the behaviour of individual tumours can be difficult. Therefore, any tool which could further stratify metastatic risk may be clinically beneficial. We sought to investigate microRNA (miRNA) expression as a marker of metastatic disease in PNETs. Tumours from 37 patients, comprising 23 with locoregional disease (L) and 14 with distant metastases (DM), underwent miRNA profiling. In total 506 miRNAs were differentially expressed between the L and DM groups, with four miRNAs (miR-3653 upregulated, and miR-4417, miR-574-3p and miR-664b-3p downregulated) showing statistical significance. A database search demonstrated that miRNA-3653 was associated with ATRX abnormalities. Mean survival between the two groups was correlated with mean expression of miRNA-3653; however, this did not reach statistical significance (p = 0.204). Although this is a small study, we conclude that miRNA-3653 upregulation may be associated with an increased risk of metastatic disease in PNETS, perhaps through interaction with ATRX and the alternate lengthening of telomeres pathway.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorDatabases, FactualFemaleGene Expression Regulation, NeoplasticHumansMaleMicroRNAsMiddle AgedNeoplasm MetastasisNeuroendocrine TumorsPancreatic NeoplasmsPredictive Value of TestsRisk AssessmentATRX protein, humanBiomarkers, TumorMicroRNAsMIRN3653 microRNA, humanX-linked Nuclear ProteinMicroRNAPancreatic neuroendocrine tumourPNET

Identifiers

PMID30767148
OpenAlexW2912869052

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.